Stocks · News reference
CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology
The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatmentStudy concludes Multikine
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 12:06 PM
- Checked
- Aug 4, 2026, 12:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.47) per share. This is a 65.44 percent increase over losses of $(1.36) per share from the same period last year.
Read original at benzingaCEL-SCI Announces Multikine Phase 3 Data Accepted For Publication In Oral Oncology, Citing 73% Five-Year Survival vs. 45% For Standard Of Care In Low PD-L1 Head And Neck Cancer
Read original at benzinga